In a set of newly released presentations, officials from the US Food and Drug Administration (FDA) explain changes to the agency's biomarker qualification program and detail early opportunities for ...

Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...

For neurodegenerative disease clinical trials, understanding how a condition is progressing and whether a treatment is having an effect can be difficult using traditional assessments alone. Biomarker ...

Alzheimer’s disease is defined by a progressive accumulation of misfolded proteins and neuronal loss that often predates clinical symptoms by years. Biomarkers aim to detect pathological hallmarks ...

Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...

Despite their importance, a significant number of biomarker strategies fail because they are added too late, are not feasible in real clinical settings, or are poorly aligned with clinical endpoints.

Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...

Industry groups and drugmakers are seeking further clarity from the US Food and Drug Administration (FDA) on draft guidance related to the qualification of biomarkers. The need for such a framework is ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

A new study identifies UBA1 as a primary candidate biomarker for multiple myeloma by integrating ubiquitination and liquid-liquid phase separation related genes into a validated prognostic model.